Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.

To investigate the effect of the variant CYP2D610 allele on the pharmacokinetics of atomoxetine and its metabolites, 4-hydroxyatomoxetine (4-HAT) and N-desmethylatomoxetine (NAT), in healthy subjects, a single oral dose of atomoxetine was administered to 62 subjects with a CYP2D6wt/*wt (*wt = *1 or 2, n = 22), CYP2D6wt/10 (n = 22) or CYP2D610/10 (n = 18) genotype. Plasma samples were then collected for 24 h after atomoxetine administration. The concentrations of atomoxetine and its metabolites were assayed using LC-MS/MS. For atomoxetine, the Cmax, AUC0-∞, t1/2 and CL/F showed genotype-dependent differences. The CYP2D610/10 and CYP2D6wt/10 groups showed 1.74- and 1.15-fold higher Cmax, 3.40- and 1.33-fold higher AUC0-∞, and 69.7 and 24.6 % lower CL/F, compared to those of the CYP2D6wt/wt group, respectively. The Cmax and t1/2 for 4-HAT were lower and longer in the CYP2D610/10 group than those in the CYP2D6wt/wt group, but the AUC0-∞ was not different between these groups. The Cmax, AUC0-∞ and t1/2 for NAT were profoundly greater in the CYP2D610/10 group than they were in the CYP2D6wt/wt group. The concentration of active moieties of atomoxetine (atomoxetine + 4-HAT) in the CYP2D610/10 group was 3.32-fold higher than that in the CYP2D6wt/wt group. The mean exposure to active moieties of atomoxetine was markedly higher in subjects with the CYP2D610/10 genotype compared to that in those with the CYP2D6wt/wt genotype. The higher systemic exposure of the active atomoxetine moieties in CYP2D610/*10 individuals may increase the risk of concentration-related adverse events of atomoxetine, although this has not yet been clinically confirmed.